MAPT and Alzheimer disease: To confirm whether the amelioration of cognitive deficits by anti-CD8a antibody treatment correlates with the loss of neuropathological hallmarks of AD, we stained coronal murine brain sections with anti-Aβ (6E10), anti-phospho-tau (AT180), and anti-total-tau (HT7) antibodies.